Dimethyl fumarate has been a mainstay of therapy for relapsing-remitting multiple sclerosis for years, valued for its combination of efficacy, oral administration, and a generally favorable long-term safety profile. The drug exerts immunomodulatory effects through several mechanisms, including activation of the nuclear factor erythroid 2-related factor 2 pathway and a characteristic reduction in circulating lymphocytes. That lymphocyte decline is usually mild to moderate and reversible, but it is precisely the reason that treatment guidelines mandate regular white blood cell counting. The Belgian authors emphasize that patient-specific factors can modulate the leukocyte response to the drug, a point supported by prior research showing that baseline counts, body characteristics, and other variables influence how far lymphocytes fall in individual patients.

The clinical sequence at the heart of the report follows a pattern that respiratory physicians know well: influenza first, bacterial pneumonia second. Influenza A damages the respiratory epithelium, disrupts mucociliary clearance, and creates conditions in which colonizing bacteria such as Streptococcus pneumoniae can invade the lower airways. In an immunocompetent host this secondary bacterial pneumonia can still become life-threatening; in a patient with drug-induced lymphopenia the barrier to invasion is substantially lower. The patient in this report progressed to severe, invasive disease requiring intensive care, illustrating how a common seasonal virus and an opportunistic bacterium can combine catastrophically when immune defenses are compromised.

Severe pneumococcal pneumonia of this kind is not merely a chest infection that responds slowly to antibiotics. Community-acquired pneumonia that deteriorates into acute respiratory distress syndrome carries substantial mortality even in modern intensive care units, and studies of mechanically ventilated patients with pneumonia have documented how frequently this syndrome complicates the course. The global definition of acute respiratory distress syndrome was updated in 2024 to improve recognition of this entity, which involves diffuse lung inflammation, impaired oxygenation, and bilateral radiographic opacities. The Belgian team situates their case within this framework, noting that the combination of viral priming, bacterial invasion, and impaired cellular immunity created the conditions for profound respiratory failure.

The first of the report’s two central lessons concerns vaccination. People with multiple sclerosis are not inherently excluded from standard vaccine recommendations; on the contrary, the ECTRIMS/EAN consensus published in 2023 provides detailed guidance on immunization in this population, urging clinicians to complete recommended vaccines before starting highly active immunotherapies and to maintain coverage thereafter. Evidence indicates that immune responses to vaccines are generally maintained in patients treated with dimethyl fumarate, and a prospective single-center study in 2024 found that seasonal influenza and pneumococcal polysaccharide vaccines remain immunogenic in patients on various disease-modifying therapies. Yet a multicenter cross-sectional study published in 2025 documented that vaccination coverage among patients with multiple sclerosis remains incomplete and variable, with determinants ranging from disease characteristics to health system factors. The case therefore functions as a concrete reminder that every patient starting or continuing immunotherapy should have a documented vaccination history, with influenza and pneumococcal vaccines addressed explicitly.

The second lesson concerns hematologic monitoring. Treatment labels and consensus recommendations call for lymphocyte counting before initiation, at three and six months, and periodically thereafter, with dose adjustment or interruption when counts fall below defined thresholds. The Common Terminology Criteria for Adverse Events provides the grading framework used to classify the severity of leukopenia and lymphopenia, and the authors apply this vocabulary to describe the degree of immune suppression in their patient. Research into interventions to increase leukocyte testing during dimethyl fumarate treatment has shown that adherence to monitoring schedules is imperfect in real-world practice, and that structured interventions can improve testing rates. The report argues that the effort required for a simple blood test is small compared with the cost of missing a progressive lymphopenia that leaves a patient vulnerable to invasive bacterial disease.

The interplay between the two lessons deserves emphasis. Vaccination reduces the probability of the triggering infections, while monitoring detects the immune vulnerability that turns those infections into emergencies. Neither measure alone is sufficient. A fully vaccinated patient can still encounter a pneumococcal serotype not covered by the vaccine or an influenza strain drifted beyond the seasonal match, and a patient with normal lymphocyte counts can still suffer severe pneumonia. But the two safeguards together shrink the risk in complementary ways: vaccination lowers exposure to the pathogens most likely to cause invasive disease, and monitoring ensures that the pharmacologically induced component of susceptibility is caught and corrected before a routine viral illness escalates. German consensus recommendations on vaccination strategies in neurological autoimmune diseases similarly stress the need to evaluate both cellular and humoral vaccine responses under immunotherapy, reflecting the same integrated logic.

For neurologists, the case underscores a division of labor that can fail in fragmented health systems. Disease-modifying therapy is typically prescribed and monitored by a neurologist, while vaccinations may be administered by general practitioners, and acute infections present first to emergency departments. When no single actor owns the whole picture, vaccination assessment can fall through the cracks, and abnormal blood counts can be reviewed without connecting them to infection risk. The authors’ experience suggests that a simple checklist at each follow-up visit, covering current lymphocyte trajectory and vaccination status against influenza and pneumococcal disease, could close many of these gaps. The intensive care perspective adds weight to the argument: the clinicians writing this report encountered the end result of the missed safeguards, not the manageable outpatient problem that earlier intervention might have preserved.

It is worth stating clearly what the case does and does not show. A single report cannot establish that dimethyl fumarate caused the severe outcome, nor can it quantify the absolute risk of invasive pneumococcal disease among patients on the drug, which appears low given the large numbers treated worldwide. Network meta-analytic evidence supports the overall efficacy and acceptable safety of immunomodulators for relapsing-remitting multiple sclerosis, and dimethyl fumarate remains an appropriate choice for many patients. The value of the report lies in its illustration of a known mechanism, viral-bacterial synergy in the lung, meeting a known vulnerability, drug-associated lymphopenia, in a setting where both were potentially modifiable. Rare severe infections are precisely the kind of outcome that routine precautions are designed to prevent, and their occurrence signals a need to audit whether those precautions were actually in place.

The broader takeaway for patients is equally direct. Anyone living with multiple sclerosis and taking an immunomodulatory therapy should know their vaccination record, ask whether influenza and pneumococcal vaccines are up to date, and confirm that blood counts are being checked on the recommended schedule. Anyone prescribing such therapy should treat the vaccination assessment and the lymphocyte count as inseparable parts of the same safety routine. The Belgian case ended in an intensive care unit, but its authors frame it not as a reason to abandon an effective drug rather as evidence that the infrastructure around the drug, the vaccines given and the blood drawn, matters as much as the prescription itself. In an era of increasingly powerful immunotherapies for neurological disease, that infrastructure is where preventable harm is most often caught, or missed.

Subject of Research: Severe pneumococcal pneumonia following influenza A in a multiple sclerosis patient treated with dimethyl fumarate

Article Title: Severe invasive pneumococcal pneumonia following influenza A in a patient with multiple sclerosis treated with dimethyl fumarate: the importance of vaccination assessment and hematologic monitoring

Article References: Severe invasive pneumococcal pneumonia following influenza A in a patient with multiple sclerosis treated with dimethyl fumarate: the importance of vaccination assessment and hematologic monitoring. (n.d.). https://doi.org/10.1007/s00415-026-14118-z

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14118-z

Keywords: multiple sclerosis, dimethyl fumarate, influenza A, pneumococcal pneumonia, lymphopenia, vaccination, hematologic monitoring, immunotherapy, Streptococcus pneumoniae, acute respiratory distress syndrome, disease-modifying therapy, intensive care

The research, led by Leonardo Palazzo and colleagues at the IRCCS San Raffaele Scientific Institute in Milan, drew on the Italian MS Registry, a nationwide repository of clinical data from people living with multiple sclerosis across the country. The team focused on patients with relapsing-remitting disease who had been treated for at least five years with one of four so-called platform therapies: the oral agents dimethyl fumarate and teriflunomide, and the injectable treatments interferon beta and glatiramer acetate. These drugs represent the long-standing backbone of first-line MS care, prescribed to hundreds of thousands of patients worldwide, yet head-to-head evidence on their effects against relapse-independent progression has remained strikingly thin.

Defining PIRA precisely is a technical challenge that has occupied the field in recent years. In this study, the investigators adopted a stringent operational definition: a confirmed worsening of disability on the Expanded Disability Status Scale that persisted for at least twelve months and occurred in the complete absence of any relapse during the relevant window. This twelve-month confirmation requirement helps filter out transient fluctuations in neurological function that can follow infections, fatigue, or heat, ensuring that the events counted as PIRA reflect genuine, sustained accumulation of impairment rather than temporary pseudoexacerbations.

From an initial pool of 1,910 eligible patients, the researchers constructed carefully balanced comparison groups using propensity score matching, a statistical technique that pairs treated individuals who share similar baseline characteristics such as age, sex, disease duration, and prior treatment history. Matching was performed separately for each drug comparison, yielding 174 matched pairs of dimethyl fumarate versus teriflunomide users and 404 matched pairs of interferon beta versus glatiramer acetate users. This design approximates the conditions of a randomized trial in a real-world setting, where treatment assignment is driven by clinical judgment rather than a protocol, and it helps reduce the confounding that typically plagues observational comparisons of therapies.

The statistical machinery applied to these matched cohorts was correspondingly rigorous. Negative binomial regression was used to model the cumulative number of PIRA events in each group, while Cox proportional hazards models estimated the time to a patient’s first PIRA event. Both approaches are standard tools in survival and event-count analysis, and their convergence strengthens the reliability of the findings. Across every comparison, the confidence intervals for the risk ratios and hazard ratios comfortably spanned the null value of one, indicating no statistically detectable difference between the therapies under study.

Specifically, teriflunomide-treated patients showed a cumulative PIRA risk ratio of 0.82 relative to those on dimethyl fumarate, with a 95 percent confidence interval of 0.47 to 1.40, and a hazard ratio of 0.81 for time to first event, with a confidence interval of 0.47 to 1.37. In the injectable comparison, glatiramer acetate versus interferon beta produced a risk ratio of 1.04 and a hazard ratio of 0.86, both similarly non-significant. When the investigators pooled the oral and injectable cohorts into a broader class-level comparison, the results again revealed no meaningful divergence, with a risk ratio of 0.79 and a hazard ratio of 1.06. In plain terms, none of the four platform drugs demonstrated a measurable advantage in shielding patients from relapse-independent disability accumulation.

The significance of this null result extends beyond the four drugs themselves. PIRA has emerged as a central concept in modern MS research because pooled analyses of clinical trial data have suggested that the majority of confirmed disability worsening in treated relapsing patients is, in fact, relapse-independent. Landmark work published in JAMA Neurology in 2020 estimated that relapse-independent progression contributes substantially to overall disability accumulation in typical relapsing disease, and subsequent cohort studies have confirmed that PIRA begins early, sometimes even after a first demyelinating event, and predicts long-term disability outcomes. If the inflammatory attacks are being controlled but patients continue to worsen silently, then understanding which therapies, if any, can modify this process becomes a question of enormous clinical weight.

The biological substrate of PIRA is thought to lie in mechanisms that conventional anti-inflammatory drugs reach only imperfectly: compartmentalized inflammation within the central nervous system, smoldering lesions with slowly expanding rims of microglial activation, meningeal inflammatory aggregates, diffuse gray matter damage, and progressive neurodegeneration that unfolds independently of peripheral immune attacks. Platform therapies such as interferon beta, glatiramer acetate, dimethyl fumarate, and teriflunomide were all developed primarily as modulators of peripheral immune activity, and the new findings are consistent with the idea that their shared mechanism of action leaves the smoldering intrathecal disease process largely untouched. Whether higher-efficacy agents, such as B-cell-depleting antibodies or potent immunosuppressants, offer better protection against PIRA remains an active area of investigation, with recent observational studies in Swiss and other cohorts beginning to explore these comparisons.

For clinicians and patients, the practical message of the Milan study is one of reassurance and clarity in therapeutic decision-making. Because the platform therapies appear equivalent with respect to PIRA risk, the choice among them can legitimately be guided by other considerations: safety profiles, tolerability, monitoring requirements, pregnancy planning, comorbidities, patient preference, and cost. Dimethyl fumarate requires regular lymphocyte and renal function monitoring; teriflunomide carries teratogenic risk and demands careful contraception counseling; interferon beta produces flu-like side effects and injection-site reactions; glatiramer acetate is generally well tolerated but demands frequent injections. None of these trade-offs, the study suggests, is offset by a differential ability to prevent silent progression.

The authors are careful to acknowledge the inherent limits of their design. Retrospective registry data, however carefully matched, cannot eliminate all confounding, and the five-year minimum treatment requirement may select for patients with milder disease courses who tolerate their therapy well. The confidence intervals, while centered near the null, are not narrow enough to exclude moderate differences between drugs, and the number of matched pairs in the oral comparison was comparatively modest. Nonetheless, the study represents one of the most direct real-world examinations of platform therapy effects on PIRA to date, and its conclusions align with a growing consensus, reflected in recent efforts to standardize PIRA definitions across the field, that relapse-independent progression is a distinct therapeutic target. As the MS treatment landscape shifts toward early use of high-efficacy agents, this work provides a sober benchmark: the older, gentler drugs, whatever their virtues, appear to stand shoulder to shoulder when it comes to the quiet accumulation of disability that no relapse ever announces.

Subject of Research: Comparative incidence of progression independent of relapse activity (PIRA) under platform disease-modifying therapies in relapsing-remitting multiple sclerosis

Article Title: Incidence of Progression Independent of Relapse Activity (PIRA) under platform disease-modifying treatment in multiple sclerosis

Article References: Palazzo, L., Clarelli, F., Giordano, A., Ferré, L., Moiola, L., Rocca, M. A., Esposito, F., Filippi, M., Clinical SanRaf MS Study Group, Missaglia, M., Visentin, G., Guido, G., Marino, V., De Simone, A., Viti, V., Zanetta, C., Margoni, M., Guerrieri, S., Petza, E., … Rossi, L. (2026). Incidence of Progression Independent of Relapse Activity (PIRA) under platform disease-modifying treatment in multiple sclerosis. Journal of Neurology, 273(10), Article 640. https://doi.org/10.1007/s00415-026-14171-8

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14171-8

Keywords: multiple sclerosis, PIRA, disease-modifying therapy, dimethyl fumarate, teriflunomide, interferon beta, glatiramer acetate, disability progression, Italian MS Registry, propensity score matching, relapsing-remitting multiple sclerosis, neuroimmunology